Trial Outcomes & Findings for Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients (NCT NCT00183625)

NCT ID: NCT00183625

Last Updated: 2026-02-09

Results Overview

• Recruitment status: COMPLETED
• Study phase: PHASE4
• Target enrollment: 107 participants
• Primary outcome timeframe: 24 months
• Results posted on: 2026-02-09

Participant Flow

Patients recruited at the Manchester Mental Health Center, Greater Los Angeles VA, and UCLA Semel Institute

Participant milestones

Measure	Risperidone Plus Supported Employment Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.	Olanzapine Plus Supported Employment Individual Placement and Support plus Olanzapine. Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.	Risperidone + Supported Employment + Skills Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.	Olanzapine + Supported Employment + Skills Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.
Overall Study STARTED	27	28	28	24
Overall Study Obtained employment	21	18	14	14
Overall Study COMPLETED	9	10	9	10
Overall Study NOT COMPLETED	18	18	19	14

Reasons for withdrawal

Measure	Risperidone Plus Supported Employment Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.	Olanzapine Plus Supported Employment Individual Placement and Support plus Olanzapine. Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.	Risperidone + Supported Employment + Skills Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.	Olanzapine + Supported Employment + Skills Participants were randomized at baseline to risperidone or olanzapine and Individual Placement and Support with or without workplace fundamentals. The WIPS was not implemented until participant obtained a job.
Overall Study Withdrawal by Subject	18	18	19	14

Baseline Characteristics

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

Baseline characteristics by cohort

Measure	Risperidone Treatment n=55 Participants	Olanzapine Treatment n=52 Participants	Total n=214 Participants Total of all reporting groups
Age, Continuous	41.8 years STANDARD_DEVIATION 10.4 • n=55 Participants	42.2 years STANDARD_DEVIATION 9.4 • n=52 Participants	42.0 years STANDARD_DEVIATION 9.9 • n=107 Participants
Sex: Female, Male Female	10 Participants n=55 Participants	9 Participants n=52 Participants	19 Participants n=107 Participants
Sex: Female, Male Male	45 Participants n=55 Participants	43 Participants n=52 Participants	88 Participants n=107 Participants

PRIMARY outcome

Timeframe: 24 months

Population: Data were analyzed for work condition (IPS with or without WIPS) and not for medication (risperidone or olanzapine)

Outcome measures

Measure	Individual Placement and Support (IPS) n=39 Participants IPS alone for risperidone and olanzapine subjects	Individual Placement and Support With Workplace Fundamentals n=28 Participants Olanzapine and Risperidone Patients included.
Total Weeks Worked	51.53 Weeks Standard Deviation 31.15	41.37 Weeks Standard Deviation 37.46

SECONDARY outcome

Timeframe: First 18 months of study

Intent was to compare medication and not work group conditions. This was initially assessed at baseline and includes total time on either risperidone or olanzapine up to 18 months.

Outcome measures

Measure	Individual Placement and Support (IPS) n=55 Participants IPS alone for risperidone and olanzapine subjects	Individual Placement and Support With Workplace Fundamentals n=52 Participants Olanzapine and Risperidone Patients included.
Body Mass Index	29.21 kg/m^2 Standard Error .99	30.4 kg/m^2 Standard Error 1.04

Adverse Events

Risperidone Treatment

Serious events: 16 serious events

Other events: 0 other events

Deaths: 0 deaths

Olanzapine Treatment

Serious events: 12 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Measure	Risperidone Treatment n=55 participants at risk	Olanzapine Treatment n=52 participants at risk
Psychiatric disorders Hospitalization	29.1% 16/55 • Number of events 34	23.1% 12/52 • Number of events 16

Other adverse events

Adverse event data not reported

Additional Information

Stephen R. Marder, M.D.

Semel Institute at UCLA

Phone: 310-268-3647

Email: marder@ucla.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place